亚盛医药-B(06855):将在2025年美国临床肿瘤学会年会公布两项最新临床进展,其中Lisaftoclax获口头报告

智通财经
May 23

智通财经APP讯,亚盛医药-B(06855)发布公告,公司将在2025年5月30日至2025年6月3日在美国伊利诺伊州芝加哥举办的2025年美国临床肿瘤学会(ASCO) 年会上,分别以口头报告和壁报形式公布APG-2575 (lisaftoclax)治疗多种血液系统肿瘤和APG-115 (alrizomadlin)治疗实体瘤的临床研究最新进展。这两项临床研究的最新数据表明lisaftoclax和alrizomadlin均具有潜在的抗肿瘤活性,且将支持对这两个品种的进一步临床开发。

Bcl-2抑制剂lisaftoclax和MDM2-p53抑制剂alrizomadlin均为亚盛细胞凋亡管线重点品种。此次lisaftoclax获选口头报告的研究为一项该品种联合阿扎胞苷治疗初治(TN)或既往接受过维奈克拉治疗的髓系恶性肿瘤患者的1b/2期临床研究。此项全球多中心研究入组患者近百人,数据显示lisaftoclax联合阿扎胞苷的耐受性良好并已显示初步疗效。值得一提的是,该研究首次公布了lisaftoclax在既往维奈克拉难治的急性髓系白血病(AML)患者及骨髓增生异常综合征(MDS)患者中的临床数据,呈现明显的治疗潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10